文献速递临床试验与 GCP流行病学与生物统计

长期连续心脏监测与常规护理对归因于大/小血管病的卒中患者房颤检出效果的比较:STROKE-AF随机临床试验

Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

STROKE-AF试验纳入496例归因于大/小血管病的卒中患者,随机分为植入式心脏监测器(ICM)组和常规护理组,随访12个月。ICM组房颤检出率显著高于常规护理组(12.1% vs 1.8%;HR 7.4,95%CI 2.6-21.3;P<.001)。

要点

  • ICM监测12个月房颤检出率显著高于常规护理(12.1% vs 1.8%;HR 7.4)。
  • ICM组操作相关不良事件发生率为1.8%(4/221)。
  • 该人群检出房颤的临床重要性尚需进一步研究。

核心结论

  • 在归因于大/小血管病的卒中患者中,ICM监测相比常规护理在12个月内检出更多房颤。

研究设计与样本

  • STROKE-AF为1:1随机、多中心(美国33个中心)临床试验,2016年4月至2019年7月纳入496例患者,主要终点随访至2020年8月。
  • 纳入标准:年龄≥60岁或50-59岁且至少1项额外卒中危险因素,且10天内发生归因于大/小血管病的索引卒中并植入ICM。
  • 干预组(n=242)在索引卒中10天内植入ICM;对照组(n=250)接受中心常规护理(包括12导联心电图、Holter、遥测或事件记录器)。
  • 主要终点为12个月内持续>30秒的房颤。

主要发现

  • 492例随机患者平均(SD)年龄67.1(9.4)岁,女性185例(37.6%),417例(84.8%)完成12个月随访。
  • 中位(IQR)CHA2DS2-VASc评分为5(4-6)。
  • 12个月时ICM组房颤检出27例(12.1%),对照组4例(1.8%);风险比7.4(95%CI 2.6-21.3);P<.001。
  • ICM组221例接受ICM者中4例(1.8%)发生ICM操作相关不良事件(1例部位感染、2例切口部位出血、1例植入部位疼痛)。

关键数值与推荐

  • 房颤定义为持续>30秒的心房颤动。
  • 主要疗效比较采用风险比7.4(95%CI 2.6-21.3),P<.001。

临床怎么用

  • 对于归因于大/小血管病的卒中患者,可考虑使用ICM进行长期连续心脏监测以提高房颤检出率。
  • 需权衡ICM操作相关不良事件风险(1.8%)。
  • 检出房颤后的临床获益尚不明确,需个体化决策。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with ischemic stroke attributed to large- or small-vessel disease are not considered at high risk for atrial fibrillation (AF), and the AF incidence rate in this population is unknown. OBJECTIVES: To determine whether long-term cardiac monitoring is more effective than usual care for AF detection in patients with stroke attributed to large- or small-vessel disease through 12 months of follow-up. DESIGN, SETTING, AND PARTICIPANTS: The STROKE-AF trial was a randomized (1:1), multicenter (33 sites in the US) clinical trial that enrolled 496 patients between April 2016 and July 2019, with primary end point follow-up through August 2020. Eligible patients were aged 60 years or older or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index stroke attributed to large- or small-vessel disease within 10 days prior to insertable cardiac monitor (ICM) insertion. INTERVENTIONS: Patients randomized to the intervention group (n = 242) received ICM insertion within 10 days of the index stroke; patients in the control group (n = 250) received site-specific usual care consisting of external cardiac monitoring, such as 12-lead electrocardiograms, Holter monitoring, telemetry, or event recorders. MAIN OUTCOMES AND MEASURES: Incident AF lasting more than 30 seconds through 12 months. RESULTS: Among 492 patients who were randomized (mean [SD] age, 67.1 [9.4] years; 185 [37.6%] women), 417 (84.8%) completed 12 months of follow-up. The median (interquartile range) CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score was 5 (4-6). AF detection at 12 months was significantly higher in the ICM group vs the control group (27 patients [12.1%] vs 4 patients [1.8%]; hazard ratio, 7.4 [95% CI, 2.6-21.3]; P < .001). Among the 221 patients in the ICM group who received an ICM, 4 (1.8%) had ICM procedure-related adverse events (1 site infection, 2 incision site hemorrhages, and 1 implant site pain). CONCLUSIONS AND RELEVANCE: Among patients with stroke attributed to large- or small-vessel disease, monitoring with an ICM compared with usual care detected significantly more AF over 12 months. However, further research is needed to understand whether identifying AF in these patients is of clinical importance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02700945.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bernstein RA, Kamel H, Granger CB, et al. Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial. JAMA. 2021. PMID: 34061145. doi:10.1001/jama.2021.6470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。